{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:11:48Z","timestamp":1761894708853},"reference-count":32,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,9,6]],"date-time":"2012-09-06T00:00:00Z","timestamp":1346889600000},"content-version":"vor","delay-in-days":4632,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Obesity Research"],"published-print":{"date-parts":[[2000,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Objective:<\/jats:italic> To evaluate the safety and efficacy of sibutramine 15 mg by mouth once per day in obese patients over a period of 6 months.<\/jats:p><jats:p><jats:italic>Research Methods and Procedures:<\/jats:italic> A monocenter, double\u2010blind, placebo controlled, parallel, prospective clinical trial was carried out. Sixty\u2010nine male and female obese patients (body mass index [BMI] &gt; 30 kg\/m<jats:sup>2<\/jats:sup>) aged 16 to 65 years entered the trial.<\/jats:p><jats:p><jats:italic>Results:<\/jats:italic> 22 of 35 patients in the sibutramine group and 9 of 34 patients in the placebo group completed the trial. The high dropout rate in the sibutramine group was due to adverse events in 3 cases, lack of efficacy (as judged by patients) in 7, loss to follow\u2010up in 2, and an orthopedic device being worn in 1; in the placebo group the dropouts were ascribed to lack of efficacy (as judged by patients) in 17 cases and to loss to follow\u2010up in 8 cases. Using the method of last observation carried forward, the weight loss in the sibutramine group was 10.27 kg (95% confidence intervals [95% CI] 7.66; 13.07) and 1.26 kg (95% CI 0.3; 2.23) in the placebo group. The BMI loss was 4.17 kg\/m<jats:sup>2<\/jats:sup> (95% CI 3.11; 5.22) in the sibutramine group and 0.53 kg\/m<jats:sup>2<\/jats:sup> (95% CI 0.13; 0.92) in the placebo group. The waist circumference reduction was 12.51 cm (95% CI 9.25; 15.77) in the sibutramine group and 3.26 cm (95% CI 1.38; 5.14) in the control group (<jats:italic>p<\/jats:italic> &lt; 0.05 by paired Student's <jats:italic>t<\/jats:italic> test for all the intragroup comparisons). Twenty\u2010three sibutramine patients had 34 adverse events, the most frequent adverse events in the sibutramine group were upper respiratory tract infections (<jats:italic>n<\/jats:italic> = 6) and constipation (<jats:italic>n<\/jats:italic> = 6); 16 placebo patients had 21 adverse events. Three sibutramine patients withdrew their informed consent when they had adverse events.<\/jats:p><jats:p><jats:italic>Discussion:<\/jats:italic> The results show that sibutramine induces significant loss of body weight and waist circumference. Cardiovascular function was not significantly affected by sibutramine. Sibutramine was well tolerated by most of the patients.<\/jats:p>","DOI":"10.1038\/oby.2000.10","type":"journal-article","created":{"date-parts":[[2008,4,15]],"date-time":"2008-04-15T11:24:22Z","timestamp":1208258662000},"page":"71-82","source":"Crossref","is-referenced-by-count":47,"title":["Six\u2010Month Treatment of Obesity with Sibutramine 15 mg; A Double\u2010Blind, Placebo\u2010Controlled Monocenter Clinical Trial in a Hispanic Population"],"prefix":"10.1002","volume":"8","author":[{"given":"Guillermina Elisa Mart\u00ednez","family":"Cuellar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto Mart\u00ednez","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cristina Revilla","family":"Monsalve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Berber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,9,6]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/jama.1994.03520030047027","article-title":"Increasing prevalence of overweight among US adults","volume":"272","author":"Kuczmarski R. J.","year":"1994","journal-title":"JAMA"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0800541"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.4.518"},{"key":"e_1_2_6_5_2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/oxfordjournals.aje.a116099","article-title":"Blood pressure in Mexican\u2010Americans, whites and blacks","volume":"134","author":"Sorel J. E.","year":"1991","journal-title":"Am J Epidemiol"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.26.9.1707"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(94)90155-4"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1995.tb00468.x"},{"issue":"1","key":"e_1_2_6_9_2","first-page":"S25","article-title":"Sibutramine: a review of the pharmacology of a novel anti\u2010obesity agent","volume":"21","author":"Stock M. J.","year":"1997","journal-title":"Int J Obes"},{"issue":"10","key":"e_1_2_6_10_2","first-page":"3","article-title":"The pharmacology of sibutramine, the first serotonin and noradrenaline reuptake inhibitor to be developed for the treatment of obesity","volume":"11","author":"Heal D. J.","year":"1997","journal-title":"La Lettre du Pharmacologue"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1998.tb00308.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1998.tb00324.x"},{"issue":"1","key":"e_1_2_6_13_2","first-page":"41S","article-title":"Sibutramine may limit decrease in resting metabolic rate during weight loss","volume":"5","author":"Wauters M.","year":"1997","journal-title":"Obes Res"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/68.6.1180"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1996.tb00544.x"},{"key":"e_1_2_6_16_2","first-page":"155","volume-title":"What Does \u201cNot Significant\u201d Really Mean? Primer of Biostatistics","author":"Glantz S. A.","year":"1992"},{"key":"e_1_2_6_17_2","first-page":"157","article-title":"Height and weight charts for Mexican adults","volume":"11","author":"Casillas L. E.","year":"1980","journal-title":"Arch Invest Med (Mex)"},{"key":"e_1_2_6_18_2","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1001\/jama.1996.03540230057036","article-title":"Long\u2010term pharmacotherapy in the management of obesity","volume":"276","author":"National Task Force on the Prevention and Treatment of Obesity","year":"1996","journal-title":"JAMA"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(96)80057-9"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1995.tb00194.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0800540"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1999.tb00701.x"},{"issue":"1","key":"e_1_2_6_23_2","first-page":"80S","article-title":"Long\u2010term weight loss with sibutramine (Meridia): a once\u2010daily serotonin and norepinephrine reuptake inhibitor","volume":"5","author":"Smith I. G.","year":"1997","journal-title":"Obes Res"},{"key":"e_1_2_6_24_2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2337\/diab.41.4.484","article-title":"Genetic and environmental determinants of type II diabetes in Mexico City and San Antonio","volume":"41","author":"Stern M. P.","year":"1992","journal-title":"Diabetes"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-9877(93)90072-X"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/1047-2797(93)90034-2"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.90.3.1542"},{"key":"e_1_2_6_28_2","first-page":"5","article-title":"Higher prevalence of diabetes in hypertensive subjects with upper body fat distribution","volume":"50","author":"Escobedo\u2010de\u2010la\u2010Pe\u00f1a J.","year":"1998","journal-title":"Rev Invest Clin"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0036-36341997000500005"},{"issue":"1","key":"e_1_2_6_30_2","first-page":"S30","article-title":"Sibutramine: a review of clinical efficacy","volume":"21","author":"Lean M. E. J.","year":"1997","journal-title":"Int J Obes"},{"issue":"10","key":"e_1_2_6_31_2","first-page":"14","article-title":"Clinical pharmacology of sibutramine","volume":"11","author":"Astrup A.","year":"1997","journal-title":"La Lettre du Pharmacologue"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199856060-00019"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1995.tb00209.x"}],"container-title":["Obesity Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Foby.2000.10","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/oby.2000.10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T07:00:59Z","timestamp":1698735659000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1038\/oby.2000.10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,1]]}},"alternative-id":["10.1038\/oby.2000.10"],"URL":"https:\/\/doi.org\/10.1038\/oby.2000.10","archive":["Portico"],"relation":{},"ISSN":["1071-7323","1550-8528"],"issn-type":[{"value":"1071-7323","type":"print"},{"value":"1550-8528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,1]]}}}